Skip to main
RNXT
RNXT logo

RenovoRx (RNXT) Stock Forecast & Price Target

RenovoRx (RNXT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

RenovoRx Inc. achieved a revenue of $422K in Q2, a notable increase from $197K in Q1, indicating positive momentum in its financial performance. The company is projected to experience substantial revenue growth, with expectations of reaching $1.3 million in 2025 and escalating to $4.5 million in 2026. As a clinical-stage biopharmaceutical company, RenovoRx's capacity for generating revenue is expected to improve significantly as it advances its proprietary targeted therapies for cancer treatment.

Bears say

RenovoRx has reported a modest revenue of $0.3 million to $0.4 million, with a net loss consistently at $2.9 million, leading to an earnings per share of $(0.08), which aligns with prior estimates but raises concerns about financial sustainability. The company operates in the challenging field of pancreatic cancer treatment, characterized by a dismal 5-year overall survival rate of 12%, underscoring the severe unmet medical need but also the substantial risks involved. In light of these factors, the continued losses, limited revenue generation, and the high-risk nature of the targeted therapies contribute to a negative outlook for RenovoRx's stock.

RenovoRx (RNXT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RenovoRx (RNXT) Forecast

Analysts have given RenovoRx (RNXT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, RenovoRx (RNXT) has a Strong Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RenovoRx (RNXT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.